Imvaq Therapeutics Signs a Service and Commercial Product License to Use ProBioGen's AGE1.CR® Vaccine Manufacturing Platform
BERLIN, Germany and NEW YORK, USA, January 06, 2022 / B3C newswire / -- ProBioGen AG is delighted to announce the execution of a service and commercial product license agreement with Imvaq Therapeutics, a biotech company developing innovative cancer immunotherapies. Under this agreement, ProBioGen develops a scalabl...